Evidence map›Paper›PMID 38516222›Full record

ArticleDialogues in health2024

Health and illness beliefs in adults with tuberculosis infection during the COVID-19 pandemic in the UK.

Ayşenur Kılıç, Amy L Clarke, Zoe Moon, Yohhei Hamada, Amy Hai Yan Chan, Ananna Rahman, Charlotte Layton, Chris J Griffiths, Dominik Zenner, Ellen Powell and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dialogues in health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ayşenur KılıçSchool of Pharmacy, University College London, London, UK.
Amy L ClarkeSchool of Pharmacy, University College London, London, UK.
Zoe MoonSchool of Pharmacy, University College London, London, UK.
Yohhei HamadaInstitute for Global Health, University College London, London, UK.
Amy Hai Yan ChanSchool of Pharmacy, University of Auckland, Auckland, New Zealand.
Ananna RahmanDepartment of Respiratory Medicine, Barts Health NHS Trust, London, UK.
Charlotte LaytonMRC Clinical Trials Unit, University College London, UK.
Chris J GriffithsCentre for Primary Care, Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Dominik ZennerCentre for Primary Care, Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Ellen PowellMRC Clinical Trials Unit, University College London, UK.
Heinke KunstRespiratory Medicine, Queen Mary University of London, London, UK.
Marc LipmanRoyal Free London NHS Foundation Trust, London, UK.
Mike MandelbaumTB Alert, Brighton, UK.
Padmasayee PapineniLondon Northwest University Healthcare NHS Trust, London, UK.
Tessa TattersallMRC Clinical Trials Unit, University College London, UK.
Trinh DuongMRC Clinical Trials Unit, University College London, UK.
Ibrahim AbubakarInstitute for Global Health, University College London, London, UK.
Molebogeng X RangakaInstitute for Global Health, University College London, London, UK.
Robert HorneSchool of Pharmacy, University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COVID-19 disrupted the TB prevention programme in the UK, especially for TB infection (TBI) care. We explore whether experience of the COVID-19 pandemic impacted on patients' perceptions of TBI and its treatment. Methods: Semi-structured interviews were conducted as part of the Research to Improve Detection and Treatment of TBI (RID-TB) programme, exploring perceptual and practical barriers to TBI treatment. Nineteen people diagnosed with TBI were interviewed between August 2020 and April 2021. Recordings were transcribed and analysed using a constant comparative approach, allowing for a dynamic and iterative exploration of themes. Themes are organised using the Perceptions and Practicalities Approach. Findings: Some participants perceived TBI as a risk factor for increased susceptibility to COVID-19, while some thought that treatment for TBI might protect against COVID-19 or mitigate its effects. Adaptations to TB services (e.g., remote follow-up) and integrated practices during the COVID-19 restrictions (e.g., medication being posted) addressed some practical barriers to TBI treatment. However, we identified beliefs about TBI and COVID-19 that are likely to act as barriers to engagement with TBI treatment, including: interpreting service delays as an indication of TBI not being serious enough for treatment and concerns about contracting COVID-19 in TB clinics. Interpretation: COVID-19 and TBI service delays influence people's perceptions and practical barriers to TBI treatment adherence. Failure to address these beliefs may lead to people's concerns about their treatment not being fully addressed. Utilised service adaptations like remote consultations to address practical barriers may be relevant beyond COVID-19. Funding: NIHR RID-TB Program (RP-PG-0217-20009).

Indexed as

Covid-19health beliefsLTBIperceptionstuberculosis

Identifiers

PMID38516222
PMCPMC10953974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.